Remepy

Remepy is a biotechnology and health care startup founded in 2022, with the slogan "Pioneering hybrid drugs". The company envisions a future where software applications will be an integral part of the treatments offered by pharmaceutical companies in the form of Hybrid Drugs™, combining a software component with traditional drug delivery via Hybrid Mechanisms of Action™.

Remepy specializes in Digital Molecules™, designed as the software components within Hybrid Drugs™. These digital interventions and treatment protocols are tailored to specific medical conditions and corresponding drugs, aiming to optimize drug performance by enhancing brain functions and balancing the patient's neuro-endocrine and neuro-immunological systems, while also boosting brain neuroplasticity.

The startup has already attracted a Seed Round investment on 01 January 2023, with Flatiron Investors and Samsung NEXT’s Q Fund as the primary backers. Remepy also partners with pharmaceutical companies to bring Hybrid Drugs™ to the market, combining their Digital Molecule™ with traditional drug components.

This innovative approach to drug development and treatment, along with the support of prominent investors, positions Remepy as a promising player in the biotechnology and healthcare industries.